

NCI's Clinical Trials Cooperative Groups National Meetings Report

Winter 2011

In This Issue

American Society for Radiation Oncology (ASTRO); American Society of Hematology (ASH), Connective Tissue Oncology Society, International Society of Pediatric Oncology (SIOP), Radiological Society of North America (RSNA), San Antonio Breast Cancer Symposium (SABCS), and Others

Cooperative Group Abstracts:

[Breast Cancer](#)

[CNS Cancer](#)

[Gastrointestinal Cancer](#)

[Genitourinary Cancer](#)

[Gynecologic Cancer](#)

[Head and Neck Cancer](#)

[Hematological Cancer](#)

[Leukemia,](#)

[Myelodysplasia, and Transplantation](#)

[Lung Cancer](#)

[Lymphoma and Plasma Cell Disorders](#)

[Sarcoma/Bone and Soft Tissue Cancers](#)

[Other Cancer](#)

NCI/CTEP Abstracts & Activities:

[DCTD/DCP Abstracts](#)

The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISOQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

[ACRIN-6654 \(SI26\)](#), [ACRIN-6654 \(SU-GG-I-62\)](#), [ACRIN-6654 \(SSE22-04\)](#): Initial results from The National Lung Screening Trial (NLST) were released by Dr. Harold Varmus, Director, NCI via a tele-briefing November 4, 2010. Initiated in 2002, the study enrolled over 53,000 current and former heavy smokers between the ages of 55-74 and compared the effects on mortality of two screening procedures for lung cancer: low-dose helical computed tomography (CT) vs. standard chest X-ray. It found that low-dose helical CT screening reduced the death rate from lung cancer in this high-risk population by a statistically significant 20 percent. An associated secondary endpoint was also reported: a 7% decline in all-cause mortality. This secondary finding, along with other secondary aims, has not yet been fully explained. The NLST was halted at the advice of the NLST Data and Safety Monitoring Board and in a letter to the NCI Director, dated October 28, 2010, the DSMB determined that the study's primary endpoint had been met, the study should be halted, and that participants should be informed of the outcome. The NLST investigators are currently conducting a full analysis on the entire NLST dataset. A plan for submission of the primary manuscript for publication is planned for the end of the first quarter of 2011. Work to analyze and prepare manuscripts that address secondary aims of the trial, such as cost-effectiveness, quality of life, and smoking cessation will follow. The initial findings do not mean that the general public should now get routine CT screening. These results relate to a specific, high-risk population and will likely be used to inform both clinical guideline and policy development. However, further analysis and modeling of the NLST data will be required.



Cooperative Group Abstracts

Breast Cancer

ACOSOG

Ellis MJ, Suman V, Hoog J, Lin H, Snider J, Parker JS, DeSchryver K, Watson M, Allred DC, Hunt K, Olson J: ACOSOG Z1031: A randomized neoadjuvant comparison between letrozole, anastrozole and exemestane for postmenopausal women with ER rich stage 2/3 breast cancer: Biomarker outcomes and the predictive value of the baseline PAM50 based intrinsic subtype. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. LBA513.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50712

Other Participant(s): CTSU

Protocol(s): ACOSOG-Z1031

ACRIN

Berg W, Zhang Z, Adams A, Mendelson E: Multiple Bilateral Similar Findings on Mammography: Results of ACRIN 6666. Radiological Society of North America (RSNA), Chicago, IL, Nov 2010. Abst. SST01-02.

<http://rsna2010.rsna.org/search/search.cfm?action=add&filter=Author&value=81428>

Protocol(s): ACRIN-6666

Berg W, Zhang Z, Yeh M, Mendelson E: Multiple Bilateral Similar Masses on Ultrasound: Results of ACRIN 6666. Radiological Society of North America (RSNA), Chicago, IL, Nov 2010. Abst. SSJ02-01.

<http://rsna2010.rsna.org/search/search.cfm?action=add&filter=Author&value=81428>

Protocol(s): ACRIN-6666

Lowry K, Lee J, Kong C, McMahon P, Gilmore M, Pisano E, Gatsonis C, Ryan P, Ozanne E, Gazelle G: Annual Screening Strategies in BRCA1 Gene Mutation Carriers: A Comparative Effectiveness Analysis. Radiological Society of North America (RSNA), Chicago, IL, Nov 2010. Abst. SST01-01.

<http://rsna2010.rsna.org/search/search.cfm?action=add&filter=Author&value=82627>

Protocol(s): ACRIN-6652

CALGB

Burstein HJ, Barry WT, Cirincione C, Chew HK, Tolaney S, Lake D, Pluard T, Blackwell K, Winer EP, Hudis CA: Fulvestrant with or without lapatinib as therapy for hormone receptor positive advanced breast cancer: A double-blinded, placebo-controlled, randomized phase III study. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. PD05-01.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1424

Other Participant(s): CTSU

Protocol(s): CALGB-40302

Ruddy KJ, Archer LE, Cohen HJ, Winer EP, Hudis CA, Muss HB, Partridge AH: Adherence, persistence and toxicity with oral CMF in older women with early stage breast cancer in CALGB 49907 (Adherence companion study 60104). San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P5-10-12.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1080

Other Participant(s): CTSU, OTHER

Protocol(s): CALGB-49907

Shulman LN, Cirrincione C, Berry DA, Becker HP, Perez E, O'Regan R, Martino S, Atkins JN, Hudis C, Winer E: Four vs 6 cycles of doxorubicin and cyclophosphamide (AC) or paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101 – A 2x2 factorial phase III trial: First results comparing 4 vs 6 cycles of therapy. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. S6-3.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1443

Other Participant(s): CTSU

Protocol(s): CALGB-40101

ECOG

Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Fetting J, Davidson NE: Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. S2-1.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_500&terms=

Other Participant(s): CALGB, NCCTG, OTHER, SWOG

Protocol(s): E1199

NCCTG

Barton D, Burger K, Novotny P, Sloan J: Self Reported Cognitive Function in Breast Cancer Survivors: A 12 Month Longitudinal Descriptive Study. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P2-14-10.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1240&terms=

Protocol(s): N00C9

Halyard MY, Dueck AC, Pisansky TM, McLaughlin SA, Pierce LJ, Marks LB, Solin LJ, Pockaj BA, Perez EA: Impact of Adjuvant Trastuzumab on Local Regional Recurrence: Data from the NCCTG N9831 Study. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P5-13-02.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1357&terms=

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, OTHER, SWOG

Protocol(s): N9831

McCullough AE, Dell'Orto P, Reinholz MM, Gelber RD, Dueck AC, Russo L, Jenkins RB, Andrighetto S, Chen B, Lingle WL, Jackisch C, Perez EA, Piccart-Gebhart MJ, Viale G: Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708). San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P3-10-36.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_790&terms=

Other Participant(s): CTSU

Protocol(s): N063D

Reinholz MM, Dueck AC, Wiktor AE, Lingle WL, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Geiger X, Perez EA: c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P2-09-08.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_797&terms=

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, OTHER, SWOG

Protocol(s): N9831

NCIC Clinical Trials Group

Goodwin RA, Jamal R, Booth CM, Goss PE, Eisenhauer EA, Tu D, Shepherd LE: Effects of Diabetes (DM), Hypertension (HTN) and Coronary Artery Disease (CAD) on Prognosis after 5 Years of Adjuvant Tamoxifen (TAM) and on Treatment Outcomes with the Use of Extended Letrozole (LET): NCIC CTG MA.17. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. PD03-04.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_808&terms=

Other Participant(s): CALGB, ECOG, NCCTG, SWOG

Protocol(s): JMA17

Goss PE, Ingle JN, Chapman J-AW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L, Pritchard KI: Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. S1-1.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_761&terms=

Other Participant(s): CTSU, NCCTG, SWOG

Protocol(s): NCIC-MA.27

Sgroi DC, Finkelstein DM, Shepherd L, Ingle JN, Rimm DL, Sasano H, Porter P, Pins M, Paik S, Ristimaki A, Pritchard KI, Tu D, Goss PE: Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P3-10-26.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1117&terms=

Other Participant(s): CALGB, ECOG, NCCTG, SWOG

Protocol(s): JMA17

Vachon CM, Brandt KR, Suman VJ, Weinshilboum R, Kosel ML, Wu F, Serie DJ, Olson JE, Buzdar AU, Shepherd LE, Goss PE, Ingle JN: Mammographic Density Response to Aromatase Inhibitor Therapy. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P2-09-03.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_693&terms=

Other Participant(s): CTSU, NCCTG
Protocol(s): NCIC-MA.27

NSABP

Ingle JN, Liu M, Wickerham DL, Schaid DJ, Mushiroda T, Kubo M, Costantino JP, Goetz MP, Ames MM, Wang L, Vogel VG, Paik S, Batzler A, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum R: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. PD05-02.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_572&terms=

Other Participant(s): OTHER
Protocol(s): NSABP-P-1, NSABP-P-2

Julian TB, Anderson SJ, Golesorkhi N, Fourchette V, Mamounas EP, Wolmark N: Prospective Outcomes for Patients with Micro-Metastases and Macro-Metastases In Sentinel Nodes: NSABP B-32 Sentinel Node Trial. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. S5-1.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1318&terms=

Protocol(s): NSABP-B-32

Julian TB, Costantino JP, Vicini FA, White JR, Arthur DW, Kuske RR, Parda DS, Mamounas EP, Curran WJ Jr, Wolmark N: Early toxicity results with 3-D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation trial. ASCO Breast Cancer Symposium, Washington, DC, Oct 2010. Abst. 92.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=100&abstractID=60277

Other Participant(s): CTSU
Protocol(s): NSABP-B-39

Mamounas EP, Anderson SJ, Bear HD, Julian TB, Geyer CE, Fisher B, Wickerham DL, Wolmark N: Predictors of loco-regional failure (LRF) in patients receiving neoadjuvant chemotherapy (NC): Results from combined analysis of NSABP B-18 and NSABP B-27. ASCO Breast Cancer Symposium, Washington, DC, Oct 2010. Abst. 90.

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=100&abstractID=60279

Protocol(s): NSABP-B-18, NSABP-B-27

Paik S: Clinical Research Award. Prediction of benefit from systemic adjuvant therapies for breast cancer [Susan G Komen for the Cure Brinker Awards for Scientific Distinction lecture]. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010.

<http://www.sabcs.org/Documents/SABCSProgramFinal2010.pdf>

Other Participant(s): CTSU, OTHER
Protocol(s): NSABP-B-14, NSABP-B-20, NSABP-B-27, NSABP-B-31, NSABP-B-45, NSABP-B-47

Tang G, Costantino JP, Crager M, Shak S, Wolmark N: Comparing the Prediction of Chemotherapy Benefit in Patients with Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and a New Measure That Integrates Clinical and Pathologic Factors with the Recurrence Score. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. S4-9.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_857&terms=

Protocol(s): NSABP-B-20

Thomas CR Jr, Glover KZ, Costantino JP, Feingold E, Wilson JW: Comparison of African American (AA) and Caucasian (C) Patients with Respect to Radiotherapy (RT) Delivery in National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Treatment Trials [Abst. 22]. Int J Radiat Oncol Biol Phys 2010; 78(3 Supp.): S10-S11.

<http://www.redjournal.org/article/S0360-3016%2810%2901040-0/fulltext>

Other Participant(s): OTHER

Protocol(s): NSABP-B-15, NSABP-B-16, NSABP-B-18, NSABP-B-22, NSABP-B-23, NSABP-B-25, NSABP-B-28

RTOG

Chafe SJ, Moughan J, Vicini FA, Wong JWC, Pass HA, Rabinovich RA, Arthur DW, Petersen IA, White JR, McCormick B: Late Toxicity and Patient Self-Assessment of Breast Appearance/Satisfaction on RTOG 0319: A Phase II Trial of Three Dimensional Conformal Radiation Therapy (3DCRT) Partial Breast Irradiation (PBI) Following Lumpectomy for Stage I and II Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P3-15-07.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_1055&terms=

Protocol(s): RTOG-0319

CNS Cancer

NCCTG

Friday BE, Buckner JC, Anderson KA, Giannini C, Kugler JW, Mazurczak M, Flynn P, Gross HM, Pajon ER, Jaeckle K, Galanis E: Phase II Trial Of Vorinostat In Combination With Bortezomib In Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Neuro-Oncology 2010; 12(Supp. 4): Abst. OT-06.

http://neuro-oncology.oxfordjournals.org/content/12/suppl_4.toc#content-block

Protocol(s): N0779

RTOG

Bae K, Baek S, Dignam J: Application of the Pattern Mixture Model to Mini Mental Status Exam (MMSE) Scores in a Radiation Therapy Oncology Group (RTOG) Trial for Brain Tumors. Joint Statistical Meetings, Vancouver, BC, Aug 2010. Abst. 307355.

http://www.amstat.org/meetings/jsm/2010/onlineprogram/index.cfm?fuseaction=abstract_details&abstractid=307355

Protocol(s): RTOG-94-02

Chakravarti A, Wang M, Robins I, Guha A, Curran W, Brachman D, Choucair A, Dolled-Filhart M, Lautenschlaeger T, Mehta M: Determinants of Therapeutic Resistance in Glioblastomas: Lessons Learned from RTOG 0211 and Beyond [Abst. 2117]. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S257.

<http://www.redjournal.org/article/S0360-3016%2810%2901587-7/fulltext>

Protocol(s): RTOG-0211

Chakravarti A, Wang M, Robins I, Guha A, Curran W, Brachman D, Choucair A, Dolled-Filhart M, Lautenschlaeger T, Mehta M: Determinants Of Therapeutic Resistance In Glioblastomas: Lessons Learned From The RTOG 0211 And Beyond [Abst. RT-01]. *Neuro-Onocology* 2010; 12(Supp. 4): iv105-iv112.

http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv105.abstract

Protocol(s): RTOG-0211

Chakravarti A, Wang M, Robins I, Guha A, Curran W, Brachman D, Choucair A, Dolled-Filhart M, Lautenschlaeger T, Mehta M: Determinants Of Therapeutic Resistance In Glioblastomas: Lessons Learned From The RTOG 0211 And Beyond. *Radiotherapy & Onocology* 2010; 96(Supp. 1): S12.

http://www.estro-events.org/Documents/ESTRO29_abstractbook_WEB.pdf

Protocol(s): RTOG-0211

Gilbert M, Wang M, Aldape K, Sorensen A, Mikkelsen T, Bokstein F, Woo S, Chmura S, Choucair A, Mehta M: RTOG 0625: A Randomized Phase II Trial of Bevacizuman with Either Irinotecan (CPT) or Dose-Dense Temozolomide (TMZ) in Recurrent Glioblastoma (GBM) [Abst. NO-14]. *Neuro-Onocology* 2010; 12(Supp. 4): iv36-iv57.

http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv36.abstract

Protocol(s): RTOG-0625

Sorensen G, Zhang Z, Boxerman J, Safriel Y, Gimpel J, Snyder B, Girardi V, Larvie M, Gilbert M: Increased Progression with T2-based Imaging during Anti-VEGF Therapy in Glioblastoma: ACRIN 6677/RTOG 0625. *Radiological Society of North America (RSNA), Chicago, IL, Nov 2010. Abst. SSA15-07.*

<http://rsna2010.rsna.org/search/search.cfm?action=add&filter=Author&value=82798>

Other Participant(s): ACRIN

Protocol(s): ACRIN-6677, RTOG-0625

SWOG

Swinnen LJ, Rankin C, Rushing EJ, Hutchins LF, Damek DM, Barger GR: Objective response rate of unresectable benign meningioma to hydroxyurea: Southwest Oncology Group phase II trial S9811. *Neuro-Onocology* 2010; 12(Supp. 4): iv69-iv78.

http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.abstract

Protocol(s): S9811

Gastrointestinal Cancer

ACOSOG

Cataldo P, Shi Q, Medich D, Pigazzi A, Oommen S, Thomas CR, Chan E, Posner MC, Garcia-Agiular J: Perioperative complications (PC) in uT2uN0 rectal cancer (RC) treated with neoadjuvant chemoradiation (CRT) and local excision (LE): preliminary results of the ACOSOG Z6041 trial. American College of Surgeons Clinical Congress, Washington, DC, Oct 2010. Abst. SE28. http://web12.facs.org/cc_program_planner/Detail_Session_2010.cfm?CCYEAR=2010&SESSION=SE28&GROUP=SE
Protocol(s): ACOSOG-Z6041

Chan E, Shi Q, Garcia-Agiular J, Wolff B, Johnson CS, Sanders B, Carrero X, Posner MC, Ota DM, Thomas CR: C.R. T: Chemoradiation (CRT) safety analysis of ACOSOG Z6041: A phase II trial of neoadjuvant (neo) CRT followed by local excision (LE) in uT2 rectal cancer (RC) [Abst. 113]. Int J Radiat Oncol Biol Phys 2010; 78(3 Supp.): S53-S54. <http://www.redjournal.org/article/S0360-3016%2810%2901133-8/fulltext>
Protocol(s): ACOSOG-Z6041

NCCTG

Sloan JA: Recent Advances in the Genetic Underpinnings of QoL from the GENEQOL Consortium [Abst. 1812]. Quality of Life Research 2010; 19(Supp. 1): 3. <http://www.springerlink.com/content/5203321j83123k3p/>
Other Participant(s): CALGB, CTSU, ECOG, NCIC Clinical Trials Group, OTHER, SWOG
Protocol(s): N0147, N9741

Sloan JA: Expansion of the Wilson & Cleary Theoretical Model to Incorporate Genetic Influences on Quality of Life [Abst. 1777]. Quality of Life Research 2010; 19(Supp. 1): 3. <http://www.springerlink.com/content/5203321j83123k3p/>
Other Participant(s): CALGB, CTSU, ECOG, NCIC Clinical Trials Group, OTHER, SWOG
Protocol(s): N0147, N9741

Sloan JA, Novotny PJ, Sargent DJ, Decker P: Calibration of Quality-Adjusted Life Years (QALYs) for Oncology Clinical Trials (OCT) [Abst. 1783]. Quality of Life Research 2010; 19(Supp. 1): 105. <http://www.springerlink.com/content/5203321j83123k3p/>
Other Participant(s): CALGB, CTSU, ECOG, NCIC Clinical Trials Group, OTHER, SWOG
Protocol(s): N0147, N9741

Stucky CH, Pockaj BA, Novotny PJ, Sloan JA, Sargent DJ, O'Connell MJ, Beart R, Skibber J, Nelson H, Weeks JC: Individual item analysis of quality of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146). Annals of Surgical Oncology 2010; 17(Suppl 1): Abst. 93. <http://www.springerlink.com/content/ytwx0tk08u24574u/fulltext.pdf>
Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, NSABP, RTOG, SWOG
Protocol(s): INT-0146

NSABP

Kerr D, O'Connell MJ, Lavery IC, Gray R, Yothers G, Quirke P, Lopatin M, Clark-Langone M, Lee M, Wolmark N: Considerations In The Development And Validation Of Genomic Tests For Cancer Recurrence And Treatment Benefit [Abst. 83PD]. *Annals of Oncology* (Oxford University Press) 2010; 21(Suppl. 8): viii44.

http://annonc.oxfordjournals.org/content/21/suppl_8/viii42.full.pdf+html

Other Participant(s): OTHER

Protocol(s): NSABP-C-01, NSABP-C-02, NSABP-C-04, NSABP-C-06

Lavery IC, O'Connell MJ, Lopatin M, Yothers G, Clark-Langone KM, Baehner F, Lee M, Shak S, Wolmark N: Number of nodes examined and the 12-gene colon cancer recurrence score predict recurrence in stage II colon cancer in 2 independent studies. *Annals of Surgical Oncology* 2010; 17(Suppl 1): Abst. P162.

<http://www.springerlink.com/content/ytwx0tk08u24574u/fulltext.pdf>

Protocol(s): NSABP-C-01, NSABP-C-02

RTOG

Berger A, Winter K, Hoffman J, Regine W, Abrams R, Safran H, Freedman G, Benson A, MacDonald J, Willett C: Five year results of US Intergroup/RTOG 9704 with postoperative CA 19-9 ≤ 90 and comparison to the CONKO-001 trial. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S100.

<http://www.redjournal.org/article/S0360-3016%2810%2901236-8/fulltext>

Other Participant(s): ECOG, SWOG

Protocol(s): RTOG-97-04

Gunderson L, Moughan J, Ajani J, Pedersen J, Benson III A, Thomas Jr. C, Mayer R, Haddock M, Rich T, Willett C: Anal carcinoma: Impact of TN category of disease on survival, relapse and colostomy failure in U.S. GI Intergroup 98-11 Phase III trial. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S55-S56.

<http://www.redjournal.org/article/S0360-3016%2810%2901137-5/fulltext>

Other Participant(s): ACOSOG, ECOG, NCCTG, NCIC Clinical Trials Group, SWOG

Protocol(s): RTOG-98-11

Kachnic L, Winter K, Myerson R, Goodyear M, Willins J, Esthappen J, Haddock M, Rotman M, Parikh P, Willet C: Early efficacy results of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-Fluorouracil and Mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S55.

<http://www.redjournal.org/article/S0360-3016%2810%2901136-3/fulltext>

Protocol(s): RTOG-0529

SWOG

Leichman LP, Goldman B, Thomas CR, Billingsley KG, Corless CL, Lenz H, Iqbal S, Benedetti JK, Gold PJ, Blanke CD: An Updated Report on the Pathologic Complete Response and Survival Outcome of Southwest Oncology Group (SWOG S0536): A Phase II Trial of Oxaliplatin (oxp) Plus Protracted Infusion 5-Fluorouracil (PIFU) and External Beam Radiation (EBRT) Prior to Surgery(s) for Potentially Curable Esophageal Adenocarcinoma (EA) with Molecular Correlates. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S28-S29.

<http://www.redjournal.org/article/S0360-3016%2810%2901080-1/fulltext>

Protocol(s): S0356

Genitourinary Cancer

COG

Fernandez CV, Davies SM, Radloff GA, Hauser J, Grundy PE, Breslow N, Anderson JR: A case-control study assessing the relationship of GST polymorphisms and the risk of development of hepatopathy on National Wilms Tumor Study-5 (NWT5-5) [Abst. #O194]. *Pediatr Blood Cancer* 2010; 55(5): 841.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Protocol(s): Q9401, Q9402

Fernandez CV, Li N, Grundy PE, Perlman EJ, Shamberger RC, Ehrlich PF, Mullen EA, Dome JS: Attitudes and practice towards the management of very low risk Wilms tumor in the Children's Oncology Group [Abst. #O075]. *Pediatr Blood Cancer* 2010; 55(5): 841-2.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Protocol(s): AREN0532

Frazier L, Billmire DF, Schlatter MG, Krailo M, Cullen JW, Rodriguez-Galindo C, Amatruda JF, Egler RA, Malogolowkin MH, Olson TA, Rescorla FJ, Ross JH, Davis MM: Stage I germ cell tumors: Outcome of a watch and wait strategy [Abst. #O073]. *Pediatr Blood Cancer* 2010; 55(5): 805.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Protocol(s): AGCT0132

RTOG

Cury F, Hunt D, Roach M, Lawton C, Gore E, Hsu I, Lustig R, Demas W, Sandler H, Shipley W: PSA Response after Short-term Hormonal Therapy Plus External Beam Radiotherapy and Outcome in Patients Treated on RTOG 9413. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S124.

<http://www.redjournal.org/article/S0360-3016%2810%2901287-3/fulltext>

Protocol(s): RTOG-94-13

Heney N, Hunt D, Shipley W, Lukka H, Major P, Grignon D, Patel M, Bahary J, Lawton C, Sandler H: RTOG 96-01: a phase III trial of anti-androgen therapy (bicalutamide) with salvage radiation therapy (RT) in pT2-3, pNO prostate cancer (PC) patients with elevated PSA levels after surgery. *Society for Urologic Oncology*, Bethesda, MD, Dec 2010.

Protocol(s): RTOG-96-01

Lawton C, Yan Y, Lee W, Gillin M, Firat S, Baikadi M, Crook J, Keuttel M, Morton G, Sandler H: Long-term Results of an RTOG Phase II Trial (00-19) of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S78-S79.

<http://www.redjournal.org/article/S0360-3016%2810%2901189-2/fulltext>

Protocol(s): RTOG-P-0019

McGowan D, Hunt D, Jones C, Amin M, Leibenhaut M, Husian S, Rotman M, Souhami L, Sandler H, Shipley W: An Update of RTOG 94-08: A Phase III trial evaluating short-term androgen deprivation prior to and during conventional-dose radiation therapy in patients with T1b T2b prostate cancer and a PSA of ≤ 20 ng/mL. *Radiotherapy & Oncology* 2010; 96(Supp. 1): S37.

http://www.estro-events.org/Documents/ESTRO29_abstractbook_WEB.pdf

Other Participant(s): OTHER

Protocol(s): RTOG-94-08

Shipley W, Hunt D, Lukka H, Major P, Heney N, Grignon D, Patel M, Bahary J, Lawton C, Sandler H: Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S27.

<http://www.redjournal.org/article/S0360-3016%2810%2901077-1/fulltext>

Other Participant(s): CTSU

Protocol(s): RTOG-96-01

Zietman A, Hunt D, Kaufman D, Uzzo R, Wu C-L, Buyyounouski M, Sandler H, Shipley W: Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S31-S32.

<http://www.redjournal.org/article/S0360-3016%2810%2901086-2/fulltext>

Protocol(s): RTOG-0233

Gynecologic Cancer

GOG

Burger RA, Brady MF, Bookman MA, Monk BJ, Walker J, Homesley H, Fowler J, Greer BE, Boente M, Liang SX: Safety and subgroup efficacy analyses in GOG218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer or Fallopian tube cancer: a Gynecologic Oncology Group study [Abst. 978PD]. *Annals of Oncology* (Oxford University Press) 2010; 21(Supp. 8): viii307.

http://annonc.oxfordjournals.org/content/21/suppl_8/viii304.full.pdf+html

Other Participant(s): CTSU

Protocol(s): GOG-0218

Burger RA, Brady MF, Fleming GF, Bookman MA, Monk BJ, Walker J, Mannel RS, Homesley H, Fowler J, Greer BE, Boente M, Liang SX: Phase III trial of bevacizumab in the primary treatment of advanced ovarian, primary peritoneal or fallopian tube cancer: a GOG study. International Gynecologic Cancer Society, Biennial Meeting, Prague, Czech Republic, Oct 2010. Abst. 2010_1348.
http://www.igcs.org/Abstract/meeting_2010_1348.html

Other Participant(s): CTSU
 Protocol(s): GOG-0218

RTOG

Gaffney D, Winter K, Kwon J, Stuhr K, Rotman M, Small Jr W, Yaremo B, Schefter T: RTOG 0417: A Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma. Int J Radiat Oncol Biol Phys 2010; 78(3 Supp.): S395.

<http://www.redjournal.org/article/S0360-3016%2810%2901906-1/fulltext>

Protocol(s): RTOG-0417

Jhingran A, Portelance L, Winter K, Miller B, Salehpour M, D'Souza D, Souhami L, Small Jr W, Gaffney D: Phase II Study of Pelvic Intensity Modulated Radiotherapy (IMRT) +/- Chemotherapy for Post-Operative Patients with Endometrial or Cervical Carcinoma (RTOG 0418). International Gynecologic Cancer Society, Biennial Meeting, Prague, Czech Republic, Oct 2010. Abst. 2010_1034.

http://www.igcs.org/Abstract/meeting_2010_1034.html

Protocol(s): RTOG-0418

Klopp A, Moughan J, Portelance L, Miller B, Salehpour M, D'Souza D, Souhami L, Small W, Gaur R, Jhingran A: Hematologic Toxicity on RTOG 0418: A Phase II Study of Post-operative IMRT for Gynecologic Cancer. Int J Radiat Oncol Biol Phys 2010; 78(3 Supp.): 258.

<http://www.redjournal.org/article/S0360-3016%2810%2901281-2/fulltext>

Protocol(s): RTOG-0417

Lee L, Winter K, Ratner E, Greven K, King S, Burke T, Underhill K, Kim H, Durkin M, Weidhaas J: The KRAS-variant and Outcome in Endometrial Adenocarcinoma: Combined Analysis of RTOG 9708 and 9905. Int J Radiat Oncol Biol Phys 2010; 78(3 Supp.): S402.

<http://www.redjournal.org/article/S0360-3016%2810%2901920-6/fulltext>

Other Participant(s): GOG, NCIC Clinical Trials Group, OTHER

Protocol(s): RTOG-97-08, RTOG-99-05

Schefter T, Winter K, Kwon J, Stuhr K, Rotman M, Yaremo B, Small W, Gaffney D: RTOG 0417: A Phase II Study of Bevacizumab in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma. Int J Radiat Oncol Biol Phys 2010; 78(3 Supp.): S395.

<http://www.redjournal.org/article/S0360-3016%2810%2901906-1/fulltext>

Protocol(s): RTOG-0417

Head and Neck Cancer

RTOG

Den R, Zhang Q, Cognetti D, Machtay M, Cooper J, Garden A, Jones C, Yom S, Ang K: Should Hypopharynx Cancer Continue to be Included in 'Multi-head and Neck' Trials within the RTOG? *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S174.

<http://www.redjournal.org/article/S0360-3016%2810%2901399-4/fulltext>

Other Participant(s): ECOG, SWOG

Protocol(s): RTOG-90-03, RTOG-95-01, RTOG-97-03

Jha N, Harris J, Seikaly H, Jacobs J, McEwan A, Robbins K, Grecula J, Sharma A, Ang K: A Phase II Study of Submandibular Salivary Gland Transfer to the Submental Space Prior to Start of Radiation Treatment for Prevention of Radiation-induced Xerostomia in Head and Neck Cancer Patients: Initial Report of RTOG-0244. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S80-S81.

<http://www.redjournal.org/article/S0360-3016%2810%2901193-4/fulltext>

Protocol(s): RTOG-0244

Lee N, Zhang Q, Kim J, Garden A, Mechalakos J, Hu K, Le Q, Glisson B, Chan A, Pfister D: Phase II Study of Concurrent and Adjuvant Chemotherapy with Intensity Modulated Radiation Therapy (IMRT) or 3D-CRT + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer (NPC)[RTOG 0615]: Preliminary Toxicity Report. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S103-S104.

<http://www.redjournal.org/article/S0360-3016%2810%2901243-5/fulltext>

Protocol(s): RTOG-0615

Wong R, James J, Sagar S, Wyatt G, Nguyen-Tan P, Singh A, Lukaszczyk B, Cardinale F, Yeh A, Berk L: RTOG 0537 Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) versus Pilocarpine in Treating Early Radiation-Induced Xerostomia (RIX): Phase II Results. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S79-S80.

<http://www.redjournal.org/article/S0360-3016%2810%2901191-0/fulltext>

Protocol(s): RTOG-0537

Hematological Cancer

ECOG

Siegel DS, Jacobus SJ, Rajkumar SV, Abonour R, Callander NS, Katz MS, Fonseca R, Vesole DH: Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial. *Blood* 2010; 116(21): Abst. 38.

<http://ash.confex.com/ash/2010/webprogram/Paper34824.html>

Other Participant(s): CTSU

Protocol(s): E4A03

Vesole DH, Jacobus SJ, Rajkumar SV, Abonour R, Callander NS, Greipp PR, Fonseca R, Katz MS, Siegel DS: Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD). Blood 2010; 116(21): Abst. 308.

<http://ash.confex.com/ash/2010/webprogram/Paper27821.html>

Other Participant(s): CTSU

Protocol(s): E4A03

Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus SJ, Morrow G: Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study. Blood 2010; 116(21): Abst. 3017.

<http://ash.confex.com/ash/2010/webprogram/Paper26532.html>

Other Participant(s): CTSU

Protocol(s): E4A03

NCIC Clinical Trials Group

Stewart AK, Trudel S, Bahlis NJ, White DJ, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Sussman J, Meyer RM, Harnett EL, Oana D, Chapman JA, Shepherd L: A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial. Blood 2010; 116(21): Abst. 39.

<http://ash.confex.com/ash/2010/webprogram/Paper33146.html>

Other Participant(s): ECOG

Protocol(s): NCIC-MY.10

Leukemia, Myelodysplasia, and Transplantation

CALGB

Attar EC, Donohue KA, Amrein PC, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees PM, Wang ES, Blum W, Booth A, Stone RM, Moser BK, Larson R: Phase II study of bortezomib added to standard daunorubicin and cytarabine induction and dose escalation of bortezomib with intermediate-dose cytarabine consolidation therapy for pts with previously untreated AML age 60-75 years: CALGB study 10502. Blood 2010; 116(21): Abst. 331.

<http://ash.confex.com/ash/2010/webprogram/Paper27661.html>

Protocol(s): CALGB-10502

Becker H, Maharry K, Radmacher MD, Margeson D, Mrózek K, Whitman SP, Wu Y, Metzeler KH, Schwind S, Holland KB, Kolitz JE, Carroll AJ, Caligiuri MA, Baer MR, Larson RA, Marcucci G, Bloomfield CD: Sole trisomy 8 in patients with de novo acute myeloid leukemia (AML) is associated with age-independent poor outcome that is modified by molecular markers and with unique gene- and microRNA (miR)-signatures: A Cancer and Leukemia Group B study. Blood 2010; 116(21): Abst. 577.

<http://ash.confex.com/ash/2010/webprogram/Paper27627.html>

Protocol(s): CALGB-20202

Blum W, Donohue K, Marcucci G, DeAngelo DJ, Uy GL, Powell BL, Stock W, Baer M, Kolitz JE, Wetzler M, Hoke E, Moser BK, Larson RA: Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study. *Blood* 2010; 116(21): Abst. 2176.

<http://ash.confex.com/ash/2010/webprogram/Paper27822.html>

Protocol(s): CALGB-10503

Gallagher R, Moser B, Racevskis J, Poiré X, Bloomfield C, Carroll A, Ketterling R, Ralston D, Schachter-Tokarz E, Zhou D, Chen I, Harvey R, Koval G, Sher D, Feusner J, Tallman M, Appelbaum F, Larson R, Powell B, Paietta E, Willman C, Stock W: Clonal markers in relapsed acute promyelocytic leukemia (APL): Clinicopathological associations and relation to all-trans retinoic acid (ATRA) treatment on intergroup phase III trial C9710. *Blood* 2010; 116(21): Abst. 1038.

<http://ash.confex.com/ash/2010/webprogram/Paper31353.html>

Other Participant(s): COG, ECOG, NCIC Clinical Trials Group, OTHER, SWOG

Protocol(s): C9710

McCarthy PL, Owzar K, Anderson KC, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Richardson PG, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Besien KV, Gentile T, Luis Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Hars V, Postiglione J, Jiang C, Bennett E, Barry SS, Bressler L, Kelly M, Sexton MRosenbaum C, Parameswaran H, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104. *Blood* 2010; 116(21): Abst. 37.

<http://ash.confex.com/ash/2010/webprogram/Paper27095.html>

Other Participant(s): CTSU, ECOG

Protocol(s): CALGB-100104

Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu Y, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD: Mutations in the Tet oncogene family member 2 (TET2) gene refine the new European LeukemiaNet risk classification of primary, cytogenetically normal acute myeloid leukemia (CN-AML) in adults: A Cancer and Leukemia Group B (CALGB) study. *Blood* 2010; 116(21): Abst. 98.

<http://ash.confex.com/ash/2010/webprogram/Paper27136.html>

Protocol(s): CALGB-20202

Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Powell BL, Shea TC, Nattom S, Hoke E, Cheson BD, Larson R: Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002. *Blood* 2010; 116(21): Abst. 858.

<http://ash.confex.com/ash/2010/webprogram/Paper28749.html>

Protocol(s): CALGB-100002

COG

Alonzo T, Ho P, Gerbing RB, Gamis AS, Raimondi SC, Hirsch B, Cooper TM, Franklin J, Pardo L, Loken MR, Meshinchi S: Conventional cytogenetics, molecular profiling, and flow cytometric response data allow the creation of a two-tiered risk-group system for risk-based therapy allocation in childhood AML- A report from the Children's Oncology Group. *Blood* 2010; 116(21): Abst. 761.

<http://ash.confex.com/ash/2010/webprogram/Paper31931.html>

Protocol(s): AAML03P1

Bhatia S, Landier W, Shangguan M, Hageman L, Leisenring WM, Kornegay N, Relling MV, Wong FL: Non-adherence to oral 6-mercaptopurine (6MP) explains ethnic differences in disease-free survival in children with acute lymphoblastic leukemia (ALL) – a Children's Oncology Group (COG) Study (AALL03N1). *Blood* 2010; 116(21): Abst. 7.

<http://ash.confex.com/ash/2010/webprogram/Paper26793.html>

Protocol(s): AALL03N1

Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Balgobind BV, Alonzo T, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson BE, Hasle H, Harrison CJ, Heerema NA, Kaspers GL, Leszl A, Litvinko N, Nigro LL, Morimoto A, Perot C: Clinical impact of additional cytogenetic aberrations and complex karyotype in pediatric 11q23/MLL-rearranged AML: Results from an International Retrospective Study. *Blood* 2010; 116(21): Abst. 762.

<http://ash.confex.com/ash/2010/webprogram/Paper32863.html>

Protocol(s): CCG-2891, CCG-2941, CCG-2961, POG-8821/22, POG-9421

Downie J, Barnette PE, Rodic V, Frazer JK, Trede NS, Devidas M, Mullighan C, Hunger SP, Miles RR, Schiffman JD: T-cell receptor gene deletions are associated with high risk features and worse outcome in childhood precursor B-cell acute lymphoblastic leukemia (ALL). *Blood* 2010; 116(21): Abst. 275.

<http://ash.confex.com/ash/2010/webprogram/Paper27430.html>

Protocol(s): POG-9906

Downing JR: The molecular pathology of acute leukemia [Abst. #SL050]. *Pediatr Blood Cancer* 2010; 55(5): 781.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Franklin AR, Alonzo T, Gerbing RB, Donohue K, Othus M, Horan JT, Estey EH, Larson RA, Woods WG: Outcome of adolescents and young adults (AYAs) with non-M3 acute myeloid leukemia (AML) treated on Children's Oncology Group (COG) trials compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) trials. *Blood* 2010; 116(21): Abst. 183.

<http://ash.confex.com/ash/2010/webprogram/Paper32360.html>

Protocol(s): AAML03P1, CCG-2861, CCG-2891, CCG-2961

Gamis A, Alonzo T, Gerbing RB, Aplenc R, Sung L, Meshinchi S, Raimondi SC, Hirsch B, Kahwash SB, McKenney AH, Winter LL, Glick KM, Byron P, Burden L, Wallas TR, Davies SM, Smith FO: Remission rates in childhood acute myeloid leukemia (AML) utilizing a dose-intensive induction regimen with or without gemtuzumab ozogamicin (GO): Initial results from the Children's Oncology Group Phase III Trial, AAML0531. *Blood* 2010; 116(21): Abst. 182.

<http://ash.confex.com/ash/2010/webprogram/Paper28100.html>

Protocol(s): AAML0531

Gutierrez A, Kentsis A, Sanda T, Etchin J, Protopopov A, Zhang J, Chin L, Silverman LB, Winter SS, Hunger SP, Sallan SE, Zha S, Alt F, Look AT: The BCL11B tumor suppressor is mutated in T-cell acute lymphoblastic leukemia. *Blood* 2010; 116(21): Abst. 4177.

<http://ash.confex.com/ash/2010/webprogram/Paper29659.html>

Protocol(s): POG-9404

Ho P, Alonzo T, Kopecky K, Miller KL, Kuhn J, Zeng R, Ries R, Gerbing RB, Fan W, Raimondi SC, Hirsch B, Oehler VG, Hurwitz C, Franklin J, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Zhao L, Bernstein ID, Radich JP, Appelbaum FR: Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: A Children's Oncology Group and Southwest Oncology Group Study. *Blood* 2010; 116(21): Abst. 2737.

<http://ash.confex.com/ash/2010/webprogram/Paper31939.html>

Other Participant(s): SWOG

Protocol(s): AAML03P1, SWOG-9031

Hughes M, Zeng R, Miller KL, Meshinchi S: Augmentation of sensitivity of FLT3/ITD assay allows detection of minimal residual disease in stem cell transplant recipients - Correlation with flow cytometric MRD assessment. *Blood* 2010; 116(21): Abst. 1717.

<http://ash.confex.com/ash/2010/webprogram/Paper33726.html>

Kang H, Wilson CS, Harvey RC, Chen I, Murphy M, Atlas SR, Bedrick E, Devidas M, Carroll AJ, Robinson B, Heerema NA, Hilden JM, Dreyer ZE, Camitta BM, Winick NJ, Carroll WL, Felix CA, Reaman GH, Hunger SP, Willman CL: Gene expression profiling reveals genes predictive of outcome in infant acute lymphoblastic leukemia (ALL) and distinctive age-related gene expression profiles (< 90 days vs. > 90 days): A Children's Oncology Group Study. *Blood* 2010; 116(21): Abst. 412.

<http://ash.confex.com/ash/2010/webprogram/Paper32417.html>

Protocol(s): P9407

Kutny MA, Alonzo T, Gerbing RB, Ho P, Geraghty D, Lange BJ, Heerema NA, Meshinchi S: TET2 SNP rs2454206 (I1762V) correlates with improved survival in pediatric acute myelogenous leukemia, A report from the Children's Oncology Group. *Blood* 2010; 116(21): Abst. 949.

<http://ash.confex.com/ash/2010/webprogram/Paper28438.html>

Protocol(s): CCG-2961

Kutny MA, Collins SJ, Loeb K, Walter R, Meshinchi S: All-trans-retinoic acid (ATRA) causes extensive differentiation in the NPM mutant, non-APL leukemic cell line OCI-AML3. *Blood* 2010; 116(21): Abst. 3305.

<http://ash.confex.com/ash/2010/webprogram/Paper32500.html>

Kutny MA, Miller KL, Alonzo T, Gerbing RB, Ho P, Gamis AS, Raimondi SC, Hirsch B, Meshinchi S: CBL mutations in pediatric acute myelogenous leukemia are a rare event, A report from the Children's Oncology Group. *Blood* 2010; 116(21): Abst. 1659.

<http://ash.confex.com/ash/2010/webprogram/Paper27191.html>

Protocol(s): AAML03P1

Kutny MA, Moser BK, Gregory JJ, Woods WG, Feusner JH, Meshinchi S: FLT3 mutations are prevalent and are significantly associated with induction death in pediatric acute promyelocytic leukemia, A report from the Children's Oncology Group. Blood 2010; 116(21): Abst. 753.

<http://ash.confex.com/ash/2010/webprogram/Paper27188.html>

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, SWOG

Protocol(s): C9710, CCG-2891, E2491

Lacayo NJ, Cohen A, Westfall M, Lackey A, Xin X, Gayko U, Putta S, Meshinchi S, Raimondi SC, Alonzo T, Arceci RJ, Ravindranath Y, Dahl GV, Cesano A: Single cell network profiling (SCNP) signatures predict response to induction therapy and relapse risk in pediatric patients with acute myeloid leukemia: Children's Oncology Group (COG) Study POG-9421. Blood 2010; 116(21): Abst. 954.

<http://ash.confex.com/ash/2010/webprogram/Paper32151.html>

Protocol(s): POG-9421

Loken MR, Alonzo T, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch B, Kahwash SB, McKenney AH, Winter LL, Glick KM, Byron P, Burden L, Wallas TR, Davies SM, Smith FO, Meshinchi S, Gamis AS: Flow cytometric assessment of post induction response in patients with sub-optimal morphologic response to induction chemotherapy- A report from the Children's Oncology Group AML Protocol AAML0531. Blood 2010; 116(21): Abst. 2740.

<http://ash.confex.com/ash/2010/webprogram/Paper32204.html>

Protocol(s): AAML0531

Maloney KW, Loh ML, Raetz EA, Borowitz MJ, Devidas M, Friedmann AM, Mattano LA, Wood BL, Winick NJ, Hunger SP, Carroll WL: Early response characteristics and blast cytogenetic features in 5,377 children with standard risk acute lymphoblastic leukemia (SR-ALL): A Children's Oncology Group (COG) Study. Blood 2010; 116(21): Abst. 414.

<http://ash.confex.com/ash/2010/webprogram/Paper34716.html>

Protocol(s): AALL0331

Matloub YH, Bostrom BC, Hunger SP, Angiolillo AL, Devidas M, La MK, Heerema NA, Winick NJ, Nachman JB, Sather H, Carroll WL, Gaynon PS: Children with Down syndrome (DS) and NCI standard risk (SR) acute lymphoblastic leukemia (ALL) have a superior five-year event-free survival (EFS) when treated with escalating intravenous methotrexate on the Children's Cancer Group Study 1991. Blood 2010; 116(21): Abst. 497.

<http://ash.confex.com/ash/2010/webprogram/Paper32211.html>

Protocol(s): CCG-1991

Meshinchi S, Alonzo T, Gerbing RB, Ho P, Gamis A, Raimondi SC, Hirsch B, Cooper TM, Franklin J, Pardo L, Loken MR: Identification of post-induction minimal residual disease by multidimensional flow cytometry identifies patients with AML at high risk of relapse and poor outcome - A report from the Children's Oncology Group. Blood 2010; 116(21): Abst. 1702.

<http://ash.confex.com/ash/2010/webprogram/Paper32135.html>

Protocol(s): AAML03P1

Meyer JA, Hogan LE, Wang J, Yang JJ, Patel JL, Levine RL, Hunger SP, Raetz EA, Mason C, Carroll WL: High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL) identifies relapse specific mutations and expression. *Blood* 2010; 116(21): Abst. 3233.

<http://ash.confex.com/ash/2010/webprogram/Paper31425.html>

Protocol(s): AALL0232, POG-9906

Pollard JA, Alonzo T, Gerbing RB, Ho P, Ries R, Zeng R, Miller KL, Kuhn J, Raimondi SC, Hirsch B, Franklin J, Gamis A, Loken MR, Meshinchi S: Association of CD33 expression level with disease risk-group classification and induction response in pediatric AML: A report from the Children's Oncology Group. *Blood* 2010; 116(21): Abst. 2732.

<http://ash.confex.com/ash/2010/webprogram/Paper31602.html>

Protocol(s): AAML03P1, AAML0531

Pollard JA, Meshinchi S, Harrington KH, Zeng R, Bernstein ID, Walter R: Sequential acquisition of somatic mutations in progenitors with differential proliferative potential in human acute myeloid leukemia. *Blood* 2010; 116(21): Abst. 755.

<http://ash.confex.com/ash/2010/webprogram/Paper34631.html>

Pope JM, Kim M, Alonzo T, Gerbing RB, Rayburg M, Radloff GA, Gamis AS, Davies SM, Perentesis JP: Oxidant pathway functional polymorphisms influence the risk of myeloid leukemia/transient myeloproliferative disorder in children with Down syndrome. *Blood* 2010; 116(21): Abst. 1680.

<http://ash.confex.com/ash/2010/webprogram/Paper29548.html>

Protocol(s): A2971

Redell MS, Ruiz MJ, Gerbing RB, Alonzo T, Tweardy D: Multiparameter FACS analysis of G-CSF and IL-6 signaling through STAT3 and STAT5 in primary pediatric AML samples. *Blood* 2010; 116(21): Abst. 1051.

<http://ash.confex.com/ash/2010/webprogram/Paper33646.html>

Protocol(s): AAML03P1, AAML10B10, AAML10B16, CCG-2891, CCG-2961

Rochowski A, Rosenberg PS, Alonzo T, Gerbing RB, Lange BJ, Alter BP: The prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia. Fanconi Anemia Research Fund Scientific Symposium, Minneapolis, MN, Oct 2010. Abst. 2232.

http://www.fanconi.org/index.php/research/annual_symposium

Protocol(s): CCG-2961

Rochowski A, Rosenberg PS, Alonzo T, Gerbing RB, Lange BJ, Alter BP: The prevalence of Fanconi anemia among patients with de novo acute myelogenous leukemia. *Blood* 2010; 116(21): Abst. 2232.

<http://ash.confex.com/ash/2010/webprogram/Paper31620.html>

Protocol(s): CCG-2961

Salzer WL, Asselin BL, Supko J, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz EA, Carroll WL, Hunger SP: Administration of Erwinia asparaginase (Erwinase) following allergy to PEG-asparaginase in children and young adults with acute lymphoblastic leukemia treated on AALL07P2 achieves therapeutic nadir serum asparaginase activity: A report from the COG. *Blood* 2010; 116(21): Abst. 2134.

<http://ash.confex.com/ash/2010/webprogram/Paper31357.html>

Protocol(s): AALL07P2

Slovak M, Ning Y, Yu L, Hunger SP, Carroll AJ, Brown TC, Campbell LJ, Wall M, Crawford E, Fang M, Kolquist K, Saleki R, Shaffer LG, Ballif B, Schultz R: Targeted microarray analyses augment the clinical cytogenetic diagnosis of acute lymphoblastic leukemia: Submicroscopic genetic events improve diagnosis, contribute to risk stratification, and provide genetic markers for minimal residual disease testing. *Blood* 2010; 116(21): Abst. 2690.

<http://ash.confex.com/ash/2010/webprogram/Paper26791.html>

Sung L, Alonzo T, Gerbing RB, Aplenc R, Meshinchi S, Burden L, Raimondi SC, Hirsch B, Kahwash SB, McKenney AH, Winter LL, Glick KM, Byron P, Wallas TR, Smith FO, Gamis A: High mortality in extreme hyperleukocytosis in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. *Blood* 2010; 116(21): Abst. 1072.

<http://ash.confex.com/ash/2010/webprogram/Paper28681.html>

Protocol(s): AAML0531

Sung L, Aplenc R, Alonzo T, Gerbing RB, Meshinchi S, Burden L, Raimondi SC, Hirsch B, Kahwash SB, McKenney AH, Winter LL, Glick KM, Byron P, Wallas TR, Smith FO, Gamis A: Severe toxicities during pediatric acute myeloid leukemia chemotherapy: A report from the Children's Oncology Group. *Blood* 2010; 116(21): Abst. 1071.

<http://ash.confex.com/ash/2010/webprogram/Paper28631.html>

Protocol(s): AAML0531

Tasian SK, Doral MY, Wood BL, Borowitz MJ, Collins-Underwood J, Harvey RC, Sakamoto KM, Willman CL, Hunger SP, Mullighan CG, Loh ML: Thymic stromal lymphopoietin stimulation of pediatric acute lymphoblastic leukemias with CRLF2 alterations induces JAK/STAT and PI3K phosphosignaling. *Blood* 2010; 116(21): Abst. 410.

<http://ash.confex.com/ash/2010/webprogram/Paper27447.html>

Protocol(s): AALL03B1, AALL09B1

Urtishak KA, Wang L, Harvey RC, Atlas SR, Chen I, Robinson B, Moukarzel L, Cao K, Devidas M, Carroll AJ, Heerema NA, Hunger S, Reaman GH, Hilden JM, Camitta B, Winick N, Carroll WL, Zhang AY, Cory L, McVeigh S, Barrett JS, Dreyer ZE, Willman CL, Felix CA: Infant acute lymphoblastic leukemias are pan-sensitive to obatoclox across molecular/cytogenetic subtypes, especially MLL-ENL, and gene expression profiles determine obatoclox IC50: A report on the Children's Oncology Group P9407 trial. *Blood* 2010; 116(21): Abst. 2757.

<http://ash.confex.com/ash/2010/webprogram/Paper34116.html>

Protocol(s): P9407

Walter R, Gudgeon CJ, Ries R, Alonzo T, Gerbing RB, Ho P, Gamis AS, Raimondi SC, Hirsch B, Franklin J, Meshinchi S: High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. *Blood* 2010; 116(21): Abst. 2762.

<http://ash.confex.com/ash/2010/webprogram/Paper34666.html>

Protocol(s): AAML03P1

Winter SS, Devidas M, Wood BL, Borowitz MJ, Loh ML, Asselin BL, Murphy JS, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Dunsmore KP: Nelarabine may be safely incorporated into a phase III study for newly diagnosed T-lineage acute lymphoblastic leukemia: A report from the Children's Oncology Group. *Blood* 2010; 116(21): Abst. 865.

<http://ash.confex.com/ash/2010/webprogram/Paper29767.html>

Protocol(s): AALL0434

Yang JJ, Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, Neale G, Winick NJ, Martin PL, Willman CL, Camitta BM, Reaman GH, Carroll WL, Loh ML, Hunger SP, Evans WE, Relling MV: ARID5B genetic polymorphisms contribute to racial disparities in childhood acute lymphoblastic leukemia: A Children's Oncology Group Study. *Blood* 2010; 116(21): Abst. 8.

<http://ash.confex.com/ash/2010/webprogram/Paper29665.html>

Protocol(s): POG-9904, POG-9905

ECOG

Cesano A, Putta S, Gayko U, Hackett J, Rosen D, Cripe LD, Sun Z, Uno H, Litzow MR, Tallman MS, Paietta EM: Single-cell network profiling (SCNP) signatures independently predict response to induction therapy in older patients with acute myeloid leukemia (AML). *Blood* 2010; 116(21): Abst. 954.

<http://ash.confex.com/ash/2010/webprogram/Paper32151.html>

Protocol(s): E3999

Cesano A, Rosen D, Putta S, Gayko U, Cripe LD, Sun Z, Uno H, Litzow MR, Tallman MS, Paietta EM: Specimen source (BM or PB) does not affect proteomic signaling in patients with AML and circulating blasts. *Blood* 2010; 116(21): Abst. 2693.

<http://ash.confex.com/ash/2010/webprogram/Paper27266.html>

Protocol(s): E3999

De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vlierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan P, Kelliher M, Kee B, Pandolfi PP, Kappes D, Gounari F, Petrie H, Van der Meulen J, Speleman F, et al: BCL11B mutations in T-cell acute lymphoblastic leukemia. *Blood* 2010; 116(21): Abst. 471.

<http://ash.confex.com/ash/2010/webprogram/Paper29879.html>

Protocol(s): INT-0132

Fielding AK, Buck G, Lazarus HM, Litzow MR, Luger SM, Marks DI, McMillan A, Moorman AV, Paietta EM, Richards SM, Tallman MS, Rowe JM, Goldstone AV: Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukaemia; Final results of the UKALLXII/ECOG2993 trial. *Blood* 2010; 116(21): Abst. 169.

<http://ash.confex.com/ash/2010/webprogram/Paper27065.html>

Protocol(s): INT-0132

Geng H, Neuberg D, Paietta EM, Deng X, Li Y, Xin Y, Racevskis J, Ketterling RP, Richards S, Tallman MS, Rowe JM, Litzow MR, Elemento O, Melnick A: Integrative Genome-Wide DNA Methylation and Gene Expression Analysis Reveals Biological and Clinical Insights In Adult Acute Lymphoblastic Leukemia. *Blood* 2010; 116(21): Abst. 852.

<http://ash.confex.com/ash/2010/webprogram/Paper33679.html>

Protocol(s): INT-0132

Kay NE, Kim HT, Kempin SJ, Rosen ST, Lazarus HM, Jelinek D, Tallman MS: Predictors of Response to Salvage Therapy for Advanced Chronic Lymphocytic Leukemia (ECOG Protocol 2903). *Blood* 2010; 116(21): Abst. 2463.

<http://ash.confex.com/ash/2010/webprogram/Paper29602.html>

Protocol(s): E2903

Litzow MR, Buck G, Dewald G, Fielding A, Ketterling RP, Lazarus HM, Luger SM, Marks DI, McMillan A, Moorman AV, Paietta EM, Richards SM, Rowe JM, Tallman MS, Goldstone AH: Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups. *Blood* 2010; 116(21): Abst. 524.

<http://ash.confex.com/ash/2010/webprogram/Paper28134.html>

Protocol(s): INT-0132

Loughran TP, Yao X, Bennett JM, Litzow MR, Evens AM, Tallman MS: Results of a Prospective Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998). *Blood* 2010; 116(21): Abst. 702.

<http://ash.confex.com/ash/2010/webprogram/Paper33234.html>

Protocol(s): E5998

Luger SM, Yao X, Paietta EM, Ketterling RP, Rybka WB, Litzow MR, Rowe JM, Larson R, Tallman MS: Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902. *Blood* 2010; 116(21): Abst. 3315.

<http://ash.confex.com/ash/2010/webprogram/Paper33833.html>

Other Participant(s): CTSU

Protocol(s): E2902

Patel JP, Abdel-Wahab O, Gonen M, Figueroa ME, Fernandez HF, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Cheng J, Viale A, Socci N, Heguy A, Ketterling RP, Gallagher RE, Litzow MR, Rowe JM, Ferrando A, Paietta EM, Tallman MS, Melnick AM, Levine R: High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. *Blood* 2010; 116(21): Abst. 851.

<http://ash.confex.com/ash/2010/webprogram/Paper32193.html>

Other Participant(s): CTSU

Protocol(s): E1900

Prebet T, Gore SD, Sun Z, Greenberg PL, Juckett MB, Malick L, Smith MR, Paietta EM, Czader M, Gabilove J, Erba H, Tallman MS: Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. *Blood* 2010; 116(21): Abst. 601.

<http://ash.confex.com/ash/2010/webprogram/Paper29350.html>

Other Participant(s): CALGB, SWOG

Protocol(s): E1905

Prebet T, Sun Z, Ketterling RP, Hicks G, Beach CL, Greenberg PL, Paietta EM, Czader M, Gabrilove J, Erba H, Tallman MS, Gore SD: A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study. *Blood* 2010; 116(21): Abst. 4013.

<http://ash.confex.com/ash/2010/webprogram/Paper29334.html>

Other Participant(s): CALGB, SWOG

Protocol(s): E1905

Rosen D, Putta S, Gayko U, Cesano A, Cripe LD, Sun Z, Litzow MR, Uno H, Tallman MS, Paietta EM: Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling. *Blood* 2010; 116(21): Abst. 2739.

<http://ash.confex.com/ash/2010/webprogram/Paper32090.html>

Protocol(s): E3999

Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger SM, Marks DI, McMillan A, Richards SM, Rowe JM, Tallman MS, Goldstone AH: Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. *Blood* 2010; 116(21): Abst. 493.

<http://ash.confex.com/ash/2010/webprogram/Paper29620.html>

Protocol(s): INT-0132

Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, Litzow MR, Rowe JM, Lucas D, Kitada S, Jelinek DF, Gribben J, Byrd JC, Reed J, Hussein MA, Appelbaum FF, Larson RA, Moore, Jr DF, Tallman MS: Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. *Blood* 2010; 116(21): Abst. 924.

<http://ash.confex.com/ash/2010/webprogram/Paper32123.html>

Other Participant(s): CALGB, SWOG

Protocol(s): E2997

Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Uno H, Vance GH, Tallman MS: Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7. *Blood* 2010; 116(21): Abst. 579.

<http://ash.confex.com/ash/2010/webprogram/Paper34379.html>

Other Participant(s): OTHER

Protocol(s): E3993, E3999, EST-1490

SWOG

Jerald RP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta EM, Wadleigh M, Larson RA, Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ: A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial. *Blood* 2010; 116(21): Abst. LBA-6.

<http://ash.confex.com/ash/2010/webprogram/Paper35005.html>

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, OTHER

Protocol(s): S0325

Pogosov-Agadjanyan E, Kopecky K, Lee H, Anderson J, Godwin J, List A, Meshinchi S, Oehler V, Petersdorf S, Willman C, Appelbaum F, Radich JP, Stirewalt D: Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients. Blood 2010; 116(21): Abst. 1679.

<http://ash.confex.com/ash/2010/webprogram/Paper29519.html>

Protocol(s): SWOG-9031, SWOG-9123, SWOG-9333, SWOG-9500

Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M, Larson R, Emanuel PD, Tallman M, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ: A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial. Blood 2010; 116(21): Abst. LBA-6.

<http://ash.confex.com/ash/2010/webprogram/Paper35005.html>

Other Participant(s): CALGB, ECOG, NCIC Clinical Trials Group, OTHER

Protocol(s): S0325

Sala-Torra O, Pogosov G, Pogosova-Agadjanyan E, Gundacker H, Forman S, O'Donnell S, Appelbaum F, Willman C, Radich JP: Analysis of CRLF2/JAK Expression and Mutation Status In Adult ALL Patients. Blood 2010; 116(21): Abst. 758.

<http://ash.confex.com/ash/2010/webprogram/Paper29791.html>

Protocol(s): S0333, SWOG-9400

Sekeres M, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman C, List A, Appelbaum F: A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). Blood 2010; 116(21): Abst. 332.

<http://ash.confex.com/ash/2010/webprogram/Paper28743.html>

Protocol(s): S0605

Lung Cancer

ACOSOG

Dupuy D, Hillman S, Fernando HC, Shepard J, Rilling W, Hong K, Putnam JB: Follow-up Spirometry in medically inoperable stage IA NSCLC after radiofrequency ablation (RFA): Report from American College of Surgeons Oncology Group Z4033. Radiological Society of North America (RSNA), Chicago, IL, Nov 2010. Abst. VO11-08.

<http://rsna2010.rsna.org/search/search.cfm?action=add&filter=Author&value=83973>

Protocol(s): ACOSOG-Z4033

ACRIN

Aberle D, Berg C: Initial Results of the National Lung Screening Trial. Radiological Society of North America (RSNA), Chicago, IL, Nov 2010. Abst. SI26.

<http://rsna2010.rsna.org/search/search.cfm?action=add&filter=Author&value=93006>

Protocol(s): ACRIN-6654

Judy P, Kruger R, Cagnon C, Seibert A, Flynn M: Entrance Skin Air Kerma from National Lung Screening Trial Chest X-ray Exams. American Association of Physicists in Medicine Annual Meeting, Philadelphia, PA, Jul 2010. Abst. SU-GG-I-62.

<http://www.aapm.org/meetings/2010AM/PRAbs.asp?mid=49&aid=13262>

Protocol(s): ACRIN-6654

Kruger R, Judy P, Flynn M, Cagnon C, Seibert A: Effective Dose Assessment for Participants in the National Lung Screening Trial Receiving Posterior-Anterior (PA) Chest X-ray Examinations. Radiological Society of North America (RSNA), Chicago, IL, Nov 2010. Abst. SSE22-04.

<http://rsna2010.rsna.org/search/search.cfm?action=add&filter=Author&value=82171>

Protocol(s): ACRIN-6654

NCCTG

Halyard MY, Tan AD, Callister MD, Ashman JB, Vora SA, Wong W, Schild SE, Atherton PJ, Sloan JA: Assessing the Clinical Significance of Real-time QOL Data in Cancer Patients Treated with Radiation Therapy(RT) [Abst. 1217]. Quality of Life Research 2010; 19(Supp. 1): 51.

<http://www.springerlink.com/content/5203321j83123k3p/>

Protocol(s): NCCTG-89-20-52

RTOG

Suntharalingam M, Paulus R, Edelman M, Krasna M, Burrows W, Gore E, Yom S, Choy H: RTOG 0229: A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and Full Dose Radiotherapy (XRT) followed by Resection and Consolidative Therapy for LA-NSCLC. Int J Radiat Oncol Biol Phys 2010; 78(3 Supp.): S111.

<http://www.redjournal.org/article/S0360-3016%2810%2901258-7/fulltext>

Protocol(s): RTOG-0229

Lymphoma and Plasma Cell Disorders

CALGB

Rubenstein JL, Johnson JL, Jung SH, Cheson BD, Kaplan LD: Intensive chemotherapy and immunotherapy, without brain irradiation, in newly diagnosed patients with primary CNS lymphoma: Results of CALGB 50202. Blood 2010; 116(21): Abst. 763.

<http://ash.confex.com/ash/2010/webprogram/Paper33494.html>

Protocol(s): CALGB-50202

COG

Day NS, Ayello J, Waxman IM, van de Ven C, Lim MS, Perkins SL, Sanger WG, Harrison L, Goldman SC, Cairo MS: Comparative genomic identification of unique signal transduction pathways and targets In pediatric Burkitt lymphoma (PBL). Blood 2010; 116(21): Abst. 631.

<http://ash.confex.com/ash/2010/webprogram/Paper27863.html>

Protocol(s): ANHL01P1

Friedman DL, Wolden SL, Constine LS, Chen L, McCarten KM, Fitzgerald TJ, De Alarcon PA, Chen AR, Hutchison RE, Ehrlich PF, Kobrinsky NL, Higman MA, Hogan SM, Roll LJ, Trippett TM, Schwartz CL: AHOD0031: A phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: A report from the Children's Oncology Group. Blood 2010; 116(21): Abst. 766.

<http://ash.confex.com/ash/2010/webprogram/Paper33086.html>

Protocol(s): AHOD0031

Horton TM, Sheehan AM, Lopez-Terrada DH, Hutchison RE, Narendra S, Wu M, Chen L, Liu H: Coordinate regulation of NF- κ B subunit expression in pediatric Hodgkin lymphoma patients with rapid early response to therapy, but not slow early response to therapy. Blood 2010; 116(21): Abst. 2680.

<http://ash.confex.com/ash/2010/webprogram/Paper30298.html>

Protocol(s): AHOD0031

Keller FG, Nachman JB, Constine LS, Thomson JW, McCarten KM, Chen L, Schwartz CL: A phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL). Blood 2010; 116(21): Abst. 767.

<http://ash.confex.com/ash/2010/webprogram/Paper32907.html>

Protocol(s): AHOD0431

Lim MS, Pulford K, Ait-Tahar K, Patel SD, Kinney MC, Perkins SL, Anderson JR, Smith LM, Cairo MS, Weitzman S, Gross TG, Kravaka JM: The autoantibody response to ALK In pediatric anaplastic large cell lymphoma: A Children's Oncology Group Report. Blood 2010; 116(21): Abst. 4130.

<http://ash.confex.com/ash/2010/webprogram/Paper27365.html>

Protocol(s): ANHL0131

ECOG

Advani RH, Hong F, Fisher R, Bartlett N, Robinson S, Gascoyne RD, Wagner H, Stiff P, Cheson B, Stewart D, Gordon LI, Kahl BS, Friedberg J, Blum K, Habermann TM, Tuscano J, Hoppe RT, Horning SJ: Randomized phase III trial comparing ABVD + radiotherapy and the Stanford V regimen in patients with stage I/II bulky mediastinal Hodgkin lymphoma: A subset analysis of the US intergroup trial E2496. Blood 2010; 116(21): Abst. 416.

<http://ash.confex.com/ash/2010/webprogram/Paper30506.html>

Other Participant(s): CALGB, NCIC Clinical Trials Group, SWOG

Protocol(s): E2496

Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani RH, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano J, Hoppe RT, Horning SJ: A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). Blood 2010; 116(21): Abst. 415.

<http://ash.confex.com/ash/2010/webprogram/Paper26704.html>

Other Participant(s): CALGB, NCIC Clinical Trials Group, SWOG

Protocol(s): E2496

Morrison VA, Hong F, Habermann TM, Fisher RI, Cheson BD, Kahl B, Horning SJ, Peterson BA: R-CHOP versus (vs) CHOP followed by maintenance rituximab (MR) vs observation in older diffuse large b-cell lymphoma (DLBCL) patients (pts): Long-term follow-up of Intergroup E4494 /C9793. *Blood* 2010; 116(21): Abst. 589.

<http://ash.confex.com/ash/2010/webprogram/Paper28235.html>

Other Participant(s): CALGB, SWOG

Protocol(s): E4494

NCCTG

Ansell SM, Tang H, Nowakowski GS, Nikcevich DA, Nelson GD, Erlichman C, Witzig TE: Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. *Blood* 2010; 116(21): Abst. 2862.

<http://ash.confex.com/ash/2010/webprogram/Paper31618.html>

Protocol(s): N0682

SWOG

Friedberg J, Unger J, Burack WR, Gopal AK, LeBlanc M, Press O, Miller TP, Fisher RI: R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433. *Blood* 2010; 116(21): Abst. 590.

<http://ash.confex.com/ash/2010/webprogram/Paper28563.html>

Protocol(s): S0433

Stopeck A, Unger J, Rimsza L, Farnsworth B, LeBlanc M, Iannone M, Fisher RI, Miller TP: Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515. *Blood* 2010; 116(21): Abst. 591.

<http://ash.confex.com/ash/2010/webprogram/Paper32478.html>

Other Participant(s): OTHER

Protocol(s): S0515

Tardif H, Yao S, Goldman B, Spier C, LeBlanc M, Rimsza L, Persky D, Miller T, Fisher RI, Ambrosone C, Briehl M: Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas. *Blood* 2010; 116(21): Abst. 321.

<http://ash.confex.com/ash/2010/webprogram/Paper30575.html>

Protocol(s): SWOG-8819

Other Cancer

COG

Frazier L, Krasker J, Villaluna D, Krailo M, Fligor BJ: Evaluation of a new method of classifying pediatric ototoxicity incorporating the concept of 'ear age' 1D [Abst. #Q018]. *Pediatr Blood Cancer* 2010; 55(5): 1009.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Hale J, Dang HM, Krailo M, Olson TA, Donachie P, Nicholson J, Billmire DF, Thornton C, Frazier L: Paediatric mediastinal germ cell tumours: Are all patients high risk? [Abst. #O075]. *Pediatr Blood Cancer* 2010; 55(5): 805.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Protocol(s): AGCT0132, AGCT01P1

Rodriguez-Galindo C: Clinical research in pediatric rare cancers [Abst. #SL15]. *Pediatr Blood Cancer* 2010; 55(5): 775-6.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Siden R, Kem R, Ostrenga A, Nicksy D, Bernhardt MB, Bartholomew JB: Creation of patient/caregiver tool for the preparation, administration and safe-handling of oral chemotherapy (3-181). American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting, Anaheim, CA, Dec 2010. Abst. 3-181.

<http://www.ashp.org/Midyear2010/GeneralInformation.aspx>

NCCTG

Neben-Wittich M, Atherton PJ, Martenson JA, Kozelsky TF, Wender DB, Behrens RJ, Loprinzi CL, Haddock MG: Assessment of Long-term Rectal Function in Patients Who Received Pelvic Radiation Therapy, Pooled Data from Two Prospective NCCTG Trials (969256 and N00CA) [Abst. 2878]. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S596.

<http://www.redjournal.org/article/S0360-3016%2810%2902363-1/fulltext>

Protocol(s): N00CA

Sloan JA, Novotny PJ, Sargent DJ, Decker P, Qin R: Clinically Significant Effect Sizes for Survival and Response Endpoints using the ½ Standard Deviation Rule [Abst. 1772]. *Quality of Life Research* 2010; 19(Supp. 1): 40.

<http://www.springerlink.com/content/5203321j83123k3p/>

Protocol(s): Multiple Trials

RTOG

Soto N, Winter K, Machtay M, Walters-Page L, Okrent K, Robinson D, McCarthy B, Hoffman W, Curran W: Are the New NCI Operational Efficiency Guidelines Achievable? A Look at the Radiation Therapy Oncology Group Studies Activated in 2009 in Comparison to the New Operational Efficiency Working Group (OEWG) Guidelines. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S490.

<http://www.redjournal.org/article/S0360-3016%2810%2902121-8/fulltext>

Sarcoma/Bone and Soft Tissue Cancers

COG

Arndt CA, Koshkina NV, Inwards C, Hawkins DS, Krailo M, Anderson PM: Inhaled GM-CSF for first pulmonary recurrence of osteosarcoma: Immunologic and surgical findings - Report from the Children's Oncology Group. Connective Tissue Oncology Society, Paris, France, Nov 2010. Abst. 830406.

<http://www.ctos.org/meeting/2010/program.pdf>

Protocol(s): AOST0221

Burke ME, Lyden E, Meza J, Ladas EJ, Arndt CA: Are weight/BMI at diagnosis or weight change on therapy predictive of toxicity in intermediate risk rhabdomyosarcoma? Children's Oncology Group report [Abst. #O173]. *Pediatr Blood Cancer* 2010; 55(5): 835.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Protocol(s): D9803

Ferrari A, Orbach D, Brennan B, Miceli R, Carli M, Bisogno G, Cecchetto G, De Salvo G, Oberlin O, Rey A, Stevens MM, Casanova M, Meazza C, Mariani L, Vannoesel MM, Devidas M, Pappo AS, Spunt SL: Initially unresected pediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European Cooperative Groups [Abst. #O175]. *Pediatr Blood Cancer* 2010; 55(5): 835-6.

<http://onlinelibrary.wiley.com/doi/10.1002/pbc.22779/abstract>

Protocol(s): POG-8653/54, POG-9553

Lin C, Donaldson SS, Meza J, Anderson JR, Lyden E, Brown CK, Morano K, Laurie F, Arndt CA, Breneman JC: The effect of radiation therapy techniques (IMRT vs. 3DCRT) on outcome in patients with intermediate risk rhabdomyosarcoma enrolled in COG D9803: A report from COG [Abst. #46]. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S21-22.

<http://www.redjournal.org/article/S0360-3016%2810%2901064-3/abstract>

Protocol(s): D9803

Malempati S, Rodeberg D, Donaldson S, Lyden E, Anderson JR, Hawkins DS, Arndt CA: Rhabdomyosarcoma in infants under one year of age: A report from the Children's Oncology Group. *Connective Tissue Oncology Society, Paris, France, Nov 2010. Abst. 826884.*

<http://www.ctos.org/meeting/2010/program.pdf>

Protocol(s): D9602, D9803, INT-0117, INT-0118, INT-0119

Marina NM, Grier HE, Womer RB, Granowetter L, Krailo M: Prognostic factors in Ewing sarcoma family of tumors (ES) treated in consecutive Children's Oncology Group (COG) studies: A report of 1444 patients. *Connective Tissue Oncology Society, Paris, France, Nov 2010. Abst. 886392.*

<http://www.ctos.org/meeting/2010/program.pdf>

RTOG

DeLaney T, Bosch W, Roberge D, Finkelstein S, Petersen I, Haddock M, Chen Y, Saito N, Kirsch D, Wang D: RTOG Sarcoma Radiation Oncologists Reach Consensus on Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) on Computed Tomography Images for Preoperative Radiotherapy of Primary Soft Tissue Sarcoma of Extremity in RTOG Studies. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S87.

<http://www.redjournal.org/article/S0360-3016%2810%2901207-1/fulltext>

Finkelstein S, Trotti A, Letson D, Caracciolo J, DeLaney T, Kraybill W, Eisenberg B, Alektiar K, Michalski J, Wang D: Radiation Therapy Oncology Group (RTOG) Consensus Panel Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Extremities. *Connective Tissue Oncology Society, Paris, France, Nov 2010. Abst. 889570.*

<http://www.ctos.org/meeting/2010/program.pdf>

Finkelstein S, Trotti A, Letson D, Caracciolo J, DeLaney T, Kraybill W, Eisenberg B, Michalski J, Wang D: Radiation Therapy Oncology Group (RTOG) Consensus Panel Atlas of Musculoskeletal Anatomy (CAMAS) for Soft Tissue Sarcoma of the Extremities. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S612.

<http://www.redjournal.org/article/S0360-3016%2810%2902399-0/fulltext>

Kraybill W, Harris J, Spiro I, Ettinger D, Letson G, DeLaney T, Blum R, Lucas D, Harmon D, Eisenberg B: Long-Term Results of a Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. *Connective Tissue Oncology Society*, Paris, France, Nov 2010. Abst. 867679.

<http://www.ctos.org/meeting/2010/program.pdf>

Other Participant(s): ECOG

Protocol(s): RTOG-95-14

Wang D, Bosch W, Kirsch D, Lozi R, Naqa I, Roberge D, Finkelstein S, Petersen I, Saito N, DeLaney T: Variations in the Gross Target Volume and Clinical Target Volume Evaluated by RTOG Sarcoma Radiation Oncologists for Preoperative Radiotherapy of Primary Extremity Sarcoma. *Int J Radiat Oncol Biol Phys* 2010; 78(3 Supp.): S620.

<http://www.redjournal.org/article/S0360-3016%2810%2902416-8/fulltext>

Wang D, Bosch W, Kirsch D, Lozi R, Naqa I, Roberge D, Finkelstein S, Petersen I, Saito N, DeLaney T: Variations in the Gross Tumor Volume and Clinical Target Volume Evaluated by RTOG Sarcoma Radiation Oncologists for Preoperative Radiotherapy of Primary Extremity Sarcoma. *Connective Tissue Oncology Society*, Paris, France, Nov 2010. Abst. 890745.

<http://www.ctos.org/meeting/2010/program.pdf>

Wang D, Bosch W, Roberge D, Finkelstein S, Petersen I, Haddock M, Chen Y, Saito N, Kirsch D, Hitchcock Y, Wolfson A, DeLaney T: RTOG Sarcoma Radiation Oncologists Reach Consensus on Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) on Computed Tomography Images for Preoperative Radiotherapy of Primary Soft Tissue Sarcoma of Extremity in RTOG Studies. *Connective Tissue Oncology Society*, Paris, France, Nov 2010. Abst. 891183.

<http://www.ctos.org/meeting/2010/program.pdf>

NCI/CTEP Abstracts & Activities

Abstracts with DCTD and DCP Investigators

Arndt CA, Langholz B, Skolnik JM, Seibel NL, Renbarger J, Zajicek A, Barrett JM: Dactinomycin and vincristine toxicity in treatment of Wilms tumor and rhabdomyosarcoma: A retrospective review from the Children's Oncology Group. *Connective Tissue Oncology Society*, Paris, France, Nov 2010. Abst. 862030.

<http://www.ctos.org/meeting/2010/program.pdf>

Daves MH, Hunger SP, Linda SB, Bowman WP, Seibel NL, Sung L, Devidas M: Longer time to the start of continuation therapy is associated with improved survival in high risk pediatric acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG). Blood 2010; 116(21): Abst. 3223.

<http://ash.confex.com/ash/2010/webprogram/Paper26593.html>

Eng-Wong J, Venzon D, Cohen P, Isaacs C, Warren R, Wedam S, Zujewski JA, Korde L, Byrne C: Effect of Exemestane on Mammographic Density in Postmenopausal Women at Risk for Breast Cancer. San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. Abst. P1-07-03.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_669&terms=

Perez EA, Dueck AC, Press MF, Chen B, Jenkins RB, Paik S, Kim C, Wiktor AE, Meyer RG, Ketterling RP, Villalobos I, Finnigan M, Buyse M, Zujewski J, Shing M, Stern H, Lingle WL, Reinholz MM, Slamon DJ: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005). San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, Dec 2010. PD10-02.

http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_874&terms=

Zhang J, Mullighan C, Harvey RC, Carroll WL, Chen I, Devidas M, Larsen EC, Edmonson M, Buetow KE, Gerhard D, Loh ML, Reaman GH, Relling MV, Smith MA, Downing JR, Willman CL, Hunger SP: Lack of somatic sequence mutations in protein tyrosine kinase genes other than the JAK kinase family in high risk B-precursor childhood acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG) high-risk (HR) ALL TARGET project. Blood 2010; 116(21): Abst. 2752.

<http://ash.confex.com/ash/2010/webprogram/Paper33259.html>

***Disclaimer:** References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References only appear under one disease heading and the Lead Cooperative Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the required information is available. Links to online abstracts are provided if they were available at the time of publication, but there is no guarantee that these links will remain active.*